Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.
A number of analytical methods were reported for the estimation of atorvastatin and ramipril from their individual dosage forms or in combination with other drugs (Valiyare, 2004; Vachareau and Neirinck, 2000). Here successful reverse phase-high performance liquid chromatographic method and spectroscopic methods developed then validated for the analysis of combined dosage form of atorvastatin and ramipril. Individual lambda-max for atorvastatin is 247 n.m and that of ramipril is 208 n.m. They intercept at 215 n.m which is fixed as wavelength for reverse phase-high performance liquid chromatographic method.
Joseph
Lincy
L
School of Pharmacy, Mekelle University, Ethiopia. mathewlincg@yahoo.com
George
Mathew
M
Rao B
Venkata Ranga
VR
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000032:analysis*; D000069059:Atorvastatin; D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D004338:Drug Combinations; D006538:Heptanoic Acids / Q000032:analysis*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000032:analysis*; D016018:Least-Squares Analysis; D011758:Pyrroles / Q000032:analysis*; D017257:Ramipril / Q000032:analysis*; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000806:Angiotensin-Converting Enzyme Inhibitors; D002214:Capsules; D004338:Drug Combinations; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D017257:Ramipril